Targeting Molecular Pathways in Human Malignancy: Current Status and Future DevelopmentFERRANDINA, Gabriella.Current pharmaceutical design (Print). 2012, Vol 18, Num 19, issn 1381-6128, 180 p.Serial Issue

Cancer Stem Cells and Novel Targets for Antitumor StrategiesPRUD'HOMME, Gérald J.Current pharmaceutical design (Print). 2012, Vol 18, Num 19, pp 2838-2849, issn 1381-6128, 12 p.Article

The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and FutureBAGNATO, Anna.Current pharmaceutical design (Print). 2012, Vol 18, Num 19, pp 2720-2733, issn 1381-6128, 14 p.Article

Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical AspectsPETRILLO, Marco; BORRIELLO, Maddalena; FUOCO, Gilda et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 19, pp 2702-2712, issn 1381-6128, 11 p.Article

Estrogen Receptor Beta in Cancer: an Attractive Target for TherapyGALLO, Daniela; DE STEFANO, Ilaria; PRISCO, Maria Grazia et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 19, pp 2734-2757, issn 1381-6128, 24 p.Article

Targeting the EGFR-family for Therapy: Biological Challenges and Clinical PerspectivePATEL, Rachana; LEUNG, Hing Y.Current pharmaceutical design (Print). 2012, Vol 18, Num 19, pp 2672-2679, issn 1381-6128, 8 p.Article

Anti-VEGF Strategies ― from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human CancerKORPANTY, Grzegorz; SMYTH, Elizabeth.Current pharmaceutical design (Print). 2012, Vol 18, Num 19, pp 2680-2701, issn 1381-6128, 22 p.Article

Targeting mTOR Pathways in Human MalignanciesFASOLO, Angelica; SESSA, Cristiana.Current pharmaceutical design (Print). 2012, Vol 18, Num 19, pp 2766-2777, issn 1381-6128, 12 p.Article

Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapyBASETTI, Rita; FERRANDINA, Gabriella; MARNEFFE, Wim et al.Nanomedicine (London. Print). 2014, Vol 9, Num 14, pp 2175-2186, issn 1743-5889, 12 p.Article

Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic ExploitationKRISHNAN, Aswini; WILSON, James; LEUNG, Hing Y et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 19, pp 2804-2810, issn 1381-6128, 7 p.Article

Chemoradiotherapy of Human Tumors: Novel Approaches from NanomedicineWERNER, Michael Edward; FOOTE, Michael Bonner; WANG, Andrew Zhuang et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 19, pp 2830-2837, issn 1381-6128, 8 p.Article

Impact of pattern of recurrence on clinical outcome of ovarian cancer patients : Clinical considerationsFERRANDINA, Gabriella; LEGGE, Francesco; SALUTARI, Vanda et al.European journal of cancer (1990). 2006, Vol 42, Num 14, pp 2296-2302, issn 0959-8049, 7 p.Article

Prognostic significance and clinical relevance of the expression of the HER family of type I receptor tyrosine kinases in human laryngeal squamous cell carcinomaALMADORI, Giovanni; BUSSU, Francesco; GESSI, Marco et al.European journal of cancer (1990). 2010, Vol 46, Num 6, pp 1144-1152, issn 0959-8049, 9 p.Article

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer A Multicentre Italian Trial in Ovarian cancer (MITO-5) studyPIGNATA, Sandro; BREDA, Enrico; PERRONE, Francesco et al.Critical reviews in oncology/hematology. 2008, Vol 66, Num 3, pp 229-236, issn 1040-8428, 8 p.Article

A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challengeFERRANDINA, Gabriella; LEGGE, Francesco; MEY, Valentina et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 3, pp 459-461, issn 0344-5704, 3 p.Article

Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatinD'AGOSTINO, Giuseppe; DISTEFANO, Mariagrazia; GREGGI, Stefano et al.Cancer chemotherapy and pharmacology. 2002, Vol 49, Num 3, pp 256-260, issn 0344-5704Article

GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapyCANTUARIA, Guilherme; FAGOTTI, Anna; FERRANDINA, Gabriella et al.Cancer. 2001, Vol 92, Num 5, pp 1144-1150, issn 0008-543XArticle

RON and Cisplatin Resistance in Ovarian Cancer Cell LinesPRISLEI, Silvia; MARIANI, Marisa; RASPAGLIO, Giuseppina et al.Oncology research. 2010, Vol 19, Num 1, pp 13-22, issn 0965-0407, 10 p.Article

Treatment of cervical cancer in Italy: Strategies and their impact on the womenDE VINCENZO, Rosa; AMADIO, Giulia; RICCI, Caterina et al.Vaccine. 2009, Vol 27, issn 0264-410X, A39-A45, SUP1Conference Paper

Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian CancerFERRANDINA, Gabriella; LUDOVISI, Manuela; SCAMBIA, Giovanni et al.Journal of clinical oncology. 2008, Vol 26, Num 6, pp 890-896, issn 0732-183X, 7 p.Article

Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinomaFAGOTTI, Anna; FERRANDINA, Gabriella; FANFANI, Francesco et al.American journal of obstetrics and gynecology. 2008, Vol 199, Num 6, pp 642-643, issn 0002-9378, 2 p.Article

Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patientsMOZZETTI, Simona; FERLINI, Cristiano; SCAMBIA, Giovanni et al.Clinical cancer research. 2005, Vol 11, Num 1, pp 298-305, issn 1078-0432, 8 p.Article

p27^Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer : Multivariate analysisMASCIULLO, Valeria; FERRANDINA, Gabriella; PUCCI, Bruna et al.Clinical cancer research. 2000, Vol 6, Num 12, pp 4816-4822, issn 1078-0432Article

Can Radicality of Surgery Be Safely Modulated on the Basis of MRI and PET/CT Imaging in Locally Advanced Cervical Cancer Patients Administered Preoperative Treatment?FERRANDINA, Gabriella; PETRILLO, Marco; RESTAINO, Gennaro et al.Cancer. 2012, Vol 118, Num 2, pp 392-403, issn 0008-543X, 12 p.Article

Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III TrialPIGNATA, Sandro; SCAMBIA, Giovanni; VERNAGLIA LOMBARDI, Alessandra et al.Journal of clinical oncology. 2011, Vol 29, Num 27, pp 3628-3635, issn 0732-183X, 8 p.Article